At EO, we systematically track how patients feel and function after starting guided cannabis care. The data below come from real people using cannabis to manage symptoms such as pain, sleep disturbance, anxiety, and nausea/vomiting, under the guidance of our clinical protocols.
We use two main types of measures:
By following patients over time, we can see what percentage experience meaningful improvement, how large those changes are, and how often they need emergency or hospital care. These are observational, real-world data, not results from a randomized clinical trial, but they offer an important window into how guided cannabis care can support symptom management in routine practice.
The sections below summarize these outcomes across the full EO program and for specific groups, including different age ranges and people living with cancer.
PROMIS Metrics
This table summarizes how quickly and effectively patients in our program experienced meaningful relief from their symptoms when using guided cannabis care. We use PROMIS questionnaires, a set of validated tools commonly used in medicine, to track changes in pain interference, sleep disturbance, anxiety, and gastrointestinal nausea and vomiting.
The percentages show the share of patients who had a clinically meaningful improvement in their PROMIS score from baseline (at least a 3-point reduction) after 1, 2, and 4 weeks of care. The sample size for each symptom at each time point is shown in parentheses.
PROMIS Metrics - Under 50 vs Over 50
Because younger and older adults can respond differently to treatments, we looked at PROMIS improvements by age group. This table compares patients under 50 and 50 and older to see whether guided cannabis care works differently across ages.
For each symptom, the percentages show the proportion of patients in each age group who achieved a meaningful improvement (at least a 3-point reduction in their PROMIS score) after 1, 2, and 4 weeks of care. Overall, both younger and older adults in our program showed meaningful improvements.
PROMIS Metrics - Cancer vs Non-Cancer Populations
Many of our patients are living with cancer and use cannabis to manage treatment-related symptoms. This table focuses on cancer patients only and shows the percentage who experienced meaningful improvement in pain interference, sleep disturbance, anxiety, and gastrointestinal nausea and vomiting after 1, 2, and 4 weeks of guided cannabis care.
As with the other PROMIS tables, “meaningful improvement” means a reduction of at least 3 points on the PROMIS T-score scale. The “n=” values show how many cancer patients had data available for each symptom and time point.
PIO Outcomes
PROMIS scores tell us about symptom severity, but we also want to know whether people can get back to the activities that matter most to them. Patient Important Outcomes (PIOs) are real-world activities such as walking, working, socializing, or managing disease-specific symptoms.
This table reports effect sizes (Cohen’s d) for changes in difficulty with these activities after starting guided cannabis care. Across all categories, the effect sizes are in the “large” range and statistically significant (p < 0.05), indicating that patients were meaningfully more able to do the activities that are important to their daily lives.
ER Visits & Hospitalizations
To understand how symptom management may relate to healthcare use, we compared published benchmark rates of monthly ER visits and unplanned hospitalizations in similar cancer populations to the rates seen among patients in our guided cannabis care program.
The “Standards in this population” row shows benchmark rates from the literature, while the “With guided cannabis care” row shows the rolling monthly average for our patients after about 4 weeks of care. These data are descriptive and do not prove cause and effect, but they suggest that patients in our program had lower rates of ER visits and hospitalizations during the first month of use.
Methodology
PROMIS Metrics: We defined a meaningful improvement as a 3-point or greater reduction in a patient’s PROMIS T-score between baseline and follow-up. The percentages in the tables show the share of patients who reached this threshold.
PIO Outcomes: PIO effect sizes were calculated using a paired Cohen’s d test comparing baseline to follow-up difficulty ratings. Effect sizes are categorized as no effect (d < 0.2), small (d ≥ 0.2), medium (d ≥ 0.5), or large (d ≥ 0.8). Larger values indicate more meaningful improvement. Statistical significance was set at p = 0.05.
ER Visit & Hospitalization Benchmarks: Benchmark rates for ER visits and unplanned hospitalizations were drawn from published data in comparable cancer populations (source: PMC3170062).
Meaningful improvements were reported by patients after one (1) week and sustained through four (4) weeks of guided cannabinoid care, particularly among people over 50 and cancer patients. Patients also reported low rates of use-limiting side effects with further reductions after receiving updated recommended product and/or dosing guidance via EO Care’s digital care platform.
New scalable, digital health offering makes personalized, clinically responsible cannabinoid guidance accessible to all older adults, adults in cancer treatment and cancer survivors.The platform was designed and tested with patients and clinicians at leading hospitals and NCI-Designated Cancer Centers.
Cancer Support Community (CSC) has teamed up with EO Care, a leader in clinically guided cannabis health solutions, to provide cancer patients, survivors, and their caregivers with comprehensive support.
Get special offers, event invites and the latest on new care offerings and product releases.
Wise Use for All
© 2025 All rights reserved. Patents pending. EO Care, Inc.
